Chronic hepatitis B affects almost 1% of Australians, many of whom are born in endemic areas outside Australia. This infection can shorten lifespan, usually because of cirrhosis or hepatocellular carcinoma. most patients acquire the infection perinatally or in childhood before migration. A small number of people acquire infection as adults via injecting drug use or sexual contact. Hepatitis B infection is usually asymptomatic, and screening using hepatitis B surface antigen should be considered for all patients from endemic countries and those with percutaneous or sexual risk factors. Improved laboratory testing for viral DNA can help identify the need for treatment and long-term risk of liver damage. Treatment is with nucleos(t)ide analogues (usually longterm) or pegylated interferon (for 12 months). This reduces inflammation, can improve liver injury and reduces progression to cirrhosis and hepatocellular carcinoma. long-term monitoring is recommended to detect reactivation of infection and hepatocellular carcinoma.
Introduction
Although Australia has traditionally been regarded as having a low prevalence of chronic hepatitis B, recent estimates suggest that 160 000 people are infected. 1, 2 The majority of these patients are born in an endemic area such as Asia, Africa, the Middle East, Central and South America, Eastern Europe (except Hungary), Mediterranean Europe (Greece, Italy, Malta, Portugal and Spain), the South Pacific and the Caribbean. High rates of infection also exist in indigenous populations. 1 
Routes of transmission
Hepatitis B transmission can occur via a number of routes including percutaneous or parenteral, horizontal transmission through mucosal contact with infected blood or bodily secretions, and during the perinatal period (see Table 1 ).
Transmission during the perinatal period is more common in patients born in endemic areas. Blood transfusions or organ transplantation are now extremely rare routes of transmission due to the rigorous screening protocols in Australia.
Natural history of infection
Chronic hepatitis B shortens the lifespan in 45% of infected men and 15% of infected women usually due to the development of cirrhosis or hepatocellular carcinoma. Following exposure, acute hepatitis B infection has an incubation period of 6-12 weeks.
Adults who acquire infection commonly develop symptoms of jaundice, anorexia, nausea, right upper quadrant discomfort and fatigue. In the perinatal setting asymptomatic subclinical hepatitis is common. While over 95% of people infected as adults will spontaneously clear the virus, this reduces to 30% in children, and 5% in infants.
Diagnosis
It is important to distinguish between patients with newly acquired hepatitis B and those with chronic infection. This may be difficult because both groups may have the hepatitis B surface antigen (HBsAg) in their blood, and may be clinically well.
Acute hepatitis B
Newly acquired infection is more likely if the patient has: n recent risk factors n negative HBsAg in last 1-2 years n high levels of specific immunoglobulin (Ig) M antibody to hepatitis B core protein in the absence of previous evidence of infection. 
managing the different phases of chronic infection
Patients with chronic hepatitis B can progress through up to four phases of disease (Table 2) . Understanding these phases is critical to determining the risk of liver damage and need for treatment. 
Recommendation
During this phase there is minimal damage and so a liver biopsy and antiviral treatment are not required. However, the majority of patients will eventually progress to phase 2 and develop active disease. Patients should therefore be advised that periodic monitoring of liver function is important to detect a rise in alanine aminotransferase. 
Phase 2 -immune clearance

Recommendation
It is common practice to initially observe patients with high alanine aminotransferase concentrations (greater than 2-5 times upper limit of normal) for three months to assess whether spontaneous HBeAg seroconversion will occur.
All patients with a persistently abnormal alanine aminotransferase should therefore be referred to a hepatologist for consideration of a liver biopsy and treatment.
Phase 3 -immune control
In this phase the immune response suppresses viral replication to low or undetectable levels. Inflammation reduces and serum alanine aminotransferase normalises. The establishment of immune control is associated with HBeAg seroconversion, and these patients are thought not to have ongoing damage. Once seroconversion occurs, patients may stay in this phase indefinitely.
Recommendation
Although most patients in this phase do not require antiviral treatment, a significant proportion will already have established cirrhosis and require regular careful assessment (Table 3) . 
Phase 4 -immune escape
In this phase the virus mutates and loses its ability to make the The two major options for chronic hepatitis B are pegylated interferon or nucleos(t)ide analogue therapy. There are advantages and disadvantages with both treatments (Table 4) .
Interferons
Pegylated interferon therapy consists of weekly subcutaneous injections usually given for 12 months. This treatment stimulates the immune system to eradicate the virus from infected hepatocytes. The benefits of pegylated interferon can persist even after treatment, and relapse rates appear to be less than with non-pegylated interferon. 4 Adverse effects include neutropenia and thrombocytopenia which require monthly blood monitoring, and dose reduction if 
Pregnancy
It is important to note that telbivudine is a category B1 drug whereas all the other nucleos(t)ide analogues are category B3.
However, experience with drugs such as lamivudine is far greater than with telbivudine so many doctors would use lamivudine in pregnancy.
Treatment initiation
In general, patients who are offered treatment have active viral replication and liver damage. Important considerations before treatment include:
n patient choice n timing of pregnancy (oral drugs are not licensed for use in pregnancy)
n risk of progression without treatment (highest in those with high alanine aminotransferase, repeated flares or significant fibrosis already)
n potential need for indefinite therapy (immune escape/HBeAg negative disease and cirrhosis)
n risk of antiviral resistance with oral nucleos(t)ide analogues n potential treatment-related adverse effects.
A general approach in treatment-naïve patients with chronic hepatitis B is outlined in Fig. 1 . 
Conclusion
Chronic hepatitis B is a common health problem in Australia. 
Self-test questions
The following statements are either true or false (answers on page 115)
5. The hepatitis B virus can develop resistance to nucleos(t)ide analogues.
6. Pegylated interferon is usually the best treatment for patients with high levels of hepatitis B virus DNA.
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